You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology
On demand events

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

Klaus Rabe
Celeste Porsbjerg
Mario Castro
MD, PhD, FERS
Klaus Rabe +2 more

On demand materials

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma
Pulmonology
expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?
Pulmonology
expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Pulmonology
expert video

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Learning objectives

  • Understand how type 2 inflammation drives the manifestations of airway remodeling found in severe asthma
  • Identify the clinical consequences of airway remodeling in severe asthma
Tags
symposium
MAT-US-2411921 v1.0 -P Exp Date: 10/28/2026

About these experts

Pulmonology
MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

Pulmonology
MD, PhD

Celeste Porsbjerg

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

Pulmonology
MD, MPH

Mario Castro

Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, University of Kansas School of Medicine

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region